Antinociceptive interaction of gabapentin with minocycline in murine diabetic neuropathy

H. F. Miranda, F. Sierralta, V. Jorquera, P. Poblete, J. C. Prieto, V. Noriega

Resultado de la investigación: Research - revisión exhaustivaArticle

  • 1 Citas

Resumen

Objective: Diabetic neuropathy (DN) is the most common complication of diabetes and pain is one of the main symptoms of diabetic neuropathy, however, currently available drugs are often ineffective and complicated by adverse events. The purpose of this research was to evaluate the antinociceptive interaction between gabapentin and minocycline in a mice experimental model of DN by streptozocin (STZ). Methods: The interaction of gabapentin with minocycline was evaluated by the writhing and hot plate tests at 3 and 7 days after STZ injection or vehicle in male CF1 mice. Results: STZ (150 mg/kg, i.p.) produced a marked increase in plasma glucose levels on day 7 (397.46 ± 29.65 mg/dL) than on day 3 (341.12 ± 35.50 mg/dL) and also developed neuropathic pain measured by algesiometric assays. Gabapentin produced similar antinociceptive activity in both writhing and hot plate tests in mice pretreated with STZ. However, minocycline was more potent in the writhing than in the hot plate test in the same type of mice. The combination of gabapentin with minocycline produced synergistic interaction in both test. Conclusion: The combination of gabapentin with minocycline in a 1:1 proportion fulfills all the criteria of multimodal analgesia and this finding suggests that the combination provide a therapeutic alternative that could be used for human neuropathic pain management.

IdiomaEnglish
Páginas91-97
Número de páginas7
PublicaciónInflammopharmacology
Volumen25
Número de edición1
DOI
EstadoPublished - 1 feb 2017

Huella dactilar

Minocycline
Diabetic Neuropathies
gabapentin
Streptozocin
Neuralgia
Diabetes Complications
Pain Management
Analgesia
Theoretical Models
Glucose
Pain
Injections
Research
Pharmaceutical Preparations
Therapeutics

Keywords

    ASJC Scopus subject areas

    • Immunology
    • Pharmacology
    • Pharmacology (medical)

    Citar esto

    Miranda, H. F. ; Sierralta, F. ; Jorquera, V. ; Poblete, P. ; Prieto, J. C. ; Noriega, V./ Antinociceptive interaction of gabapentin with minocycline in murine diabetic neuropathy. En: Inflammopharmacology. 2017 ; Vol. 25, N.º 1. pp. 91-97
    @article{628a8e5d8f944ac08afd98c50222e025,
    title = "Antinociceptive interaction of gabapentin with minocycline in murine diabetic neuropathy",
    abstract = "Objective: Diabetic neuropathy (DN) is the most common complication of diabetes and pain is one of the main symptoms of diabetic neuropathy, however, currently available drugs are often ineffective and complicated by adverse events. The purpose of this research was to evaluate the antinociceptive interaction between gabapentin and minocycline in a mice experimental model of DN by streptozocin (STZ). Methods: The interaction of gabapentin with minocycline was evaluated by the writhing and hot plate tests at 3 and 7 days after STZ injection or vehicle in male CF1 mice. Results: STZ (150 mg/kg, i.p.) produced a marked increase in plasma glucose levels on day 7 (397.46 ± 29.65 mg/dL) than on day 3 (341.12 ± 35.50 mg/dL) and also developed neuropathic pain measured by algesiometric assays. Gabapentin produced similar antinociceptive activity in both writhing and hot plate tests in mice pretreated with STZ. However, minocycline was more potent in the writhing than in the hot plate test in the same type of mice. The combination of gabapentin with minocycline produced synergistic interaction in both test. Conclusion: The combination of gabapentin with minocycline in a 1:1 proportion fulfills all the criteria of multimodal analgesia and this finding suggests that the combination provide a therapeutic alternative that could be used for human neuropathic pain management.",
    keywords = "Diabetes, Gabapentin, Minocycline, Neuropathy, Streptozocin, Synergism",
    author = "Miranda, {H. F.} and F. Sierralta and V. Jorquera and P. Poblete and Prieto, {J. C.} and V. Noriega",
    year = "2017",
    month = "2",
    doi = "10.1007/s10787-017-0308-5",
    volume = "25",
    pages = "91--97",
    journal = "Inflammopharmacology",
    issn = "0925-4692",
    publisher = "Birkhauser Verlag Basel",
    number = "1",

    }

    Antinociceptive interaction of gabapentin with minocycline in murine diabetic neuropathy. / Miranda, H. F.; Sierralta, F.; Jorquera, V.; Poblete, P.; Prieto, J. C.; Noriega, V.

    En: Inflammopharmacology, Vol. 25, N.º 1, 01.02.2017, p. 91-97.

    Resultado de la investigación: Research - revisión exhaustivaArticle

    TY - JOUR

    T1 - Antinociceptive interaction of gabapentin with minocycline in murine diabetic neuropathy

    AU - Miranda,H. F.

    AU - Sierralta,F.

    AU - Jorquera,V.

    AU - Poblete,P.

    AU - Prieto,J. C.

    AU - Noriega,V.

    PY - 2017/2/1

    Y1 - 2017/2/1

    N2 - Objective: Diabetic neuropathy (DN) is the most common complication of diabetes and pain is one of the main symptoms of diabetic neuropathy, however, currently available drugs are often ineffective and complicated by adverse events. The purpose of this research was to evaluate the antinociceptive interaction between gabapentin and minocycline in a mice experimental model of DN by streptozocin (STZ). Methods: The interaction of gabapentin with minocycline was evaluated by the writhing and hot plate tests at 3 and 7 days after STZ injection or vehicle in male CF1 mice. Results: STZ (150 mg/kg, i.p.) produced a marked increase in plasma glucose levels on day 7 (397.46 ± 29.65 mg/dL) than on day 3 (341.12 ± 35.50 mg/dL) and also developed neuropathic pain measured by algesiometric assays. Gabapentin produced similar antinociceptive activity in both writhing and hot plate tests in mice pretreated with STZ. However, minocycline was more potent in the writhing than in the hot plate test in the same type of mice. The combination of gabapentin with minocycline produced synergistic interaction in both test. Conclusion: The combination of gabapentin with minocycline in a 1:1 proportion fulfills all the criteria of multimodal analgesia and this finding suggests that the combination provide a therapeutic alternative that could be used for human neuropathic pain management.

    AB - Objective: Diabetic neuropathy (DN) is the most common complication of diabetes and pain is one of the main symptoms of diabetic neuropathy, however, currently available drugs are often ineffective and complicated by adverse events. The purpose of this research was to evaluate the antinociceptive interaction between gabapentin and minocycline in a mice experimental model of DN by streptozocin (STZ). Methods: The interaction of gabapentin with minocycline was evaluated by the writhing and hot plate tests at 3 and 7 days after STZ injection or vehicle in male CF1 mice. Results: STZ (150 mg/kg, i.p.) produced a marked increase in plasma glucose levels on day 7 (397.46 ± 29.65 mg/dL) than on day 3 (341.12 ± 35.50 mg/dL) and also developed neuropathic pain measured by algesiometric assays. Gabapentin produced similar antinociceptive activity in both writhing and hot plate tests in mice pretreated with STZ. However, minocycline was more potent in the writhing than in the hot plate test in the same type of mice. The combination of gabapentin with minocycline produced synergistic interaction in both test. Conclusion: The combination of gabapentin with minocycline in a 1:1 proportion fulfills all the criteria of multimodal analgesia and this finding suggests that the combination provide a therapeutic alternative that could be used for human neuropathic pain management.

    KW - Diabetes

    KW - Gabapentin

    KW - Minocycline

    KW - Neuropathy

    KW - Streptozocin

    KW - Synergism

    UR - http://www.scopus.com/inward/record.url?scp=85011593447&partnerID=8YFLogxK

    U2 - 10.1007/s10787-017-0308-5

    DO - 10.1007/s10787-017-0308-5

    M3 - Article

    VL - 25

    SP - 91

    EP - 97

    JO - Inflammopharmacology

    T2 - Inflammopharmacology

    JF - Inflammopharmacology

    SN - 0925-4692

    IS - 1

    ER -